APhA urges regulators to revise review process of healthcare vertical mergers

28 February 2020

The American Pharmacists Association (APhA) says it has submitted comments to the Federal Trade Commission (FTC) and the US Department of Justice (DoJ) Antitrust Division addressing the impact vertical mergers are having on the pharmacy supply chain, medication pricing and patient access and choice.

Vertical mergers, which combine two or more companies that operate at different levels in the same supply chain, have created a highly concentrated marketplace where only a few large Pharmacy Benefit Managers (PBM) control about three-quarters of all prescription claims, and integrated health care systems restrict access.

In the comments, the APhA recommends that, as part of the evaluation of healthcare vertical mergers, there be:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK